Combining chemotherapy with immunotherapy in early lung cancer patients causes 36% of tumors to disappear, new study finds.
LatinAmerican Post | Brandon Martínez Salazar
Escucha este artículo
The hopeful study carried out by the Spanish Lung Cancer Group showed how a new treatment developed for this pathology opens up a series of possibilities that will reduce the mortality rate that currently exists.
Without a doubt, this research is one of the most important advances that has been made in decades fighting a disease that kills thousands of people every year around the world.
However, the results of the study are about to be presented next week in the United States during a conference that brings together the best Oncology specialists on the planet. However, it is important to note that the FDA (US Drug Agency) has approved the new treatment for lung cancer.
What is this breakthrough and what is the treatment?
For decades, lung cancer has become the disease with the highest mortality rate. It is so deadly that only 30% of patients with early-stage tumors survive more than five years.
This new study, which is considered by the scientific community as a historic advance, managed to mix two types of treatments that left amazing results and gives hope for a change in the medical paradigm.
In this sense, the clinical trial known as NADIM II, carried out by the GECP in Spain, showed that administering chemotherapy with immunotherapy in a patient with early lung cancer and prior to undergoing surgery extends the life cycle of the people who suffer from it and reduces the progression of malignant cells by up to 60%.
We recommend you read: Hope Emerges Against Metastatic Breast Cancer
This research was carried out in 86 patients from different hospitals in Spain, of which 93% received the combination of the two mentioned treatments and then underwent surgery. Leaving as a result that 36.8% of the operated patients presented an absence of the tumor. However, compared to 69% of those treated with chemotherapy, only 6% after surgery presented the same absence.
"With these new follow-up data we can highlight that 80% of the patients included in this study are still alive at three years and 69.6% of the patients included in the research have not had disease progression", says Mariano Provencio, president of the GECP in the article published on the official web portal.
Finally, it should be noted that the clinical trial also left patients with great tolerance, since it consists of a short cycle of three administrations.
What could this discovery entail?
Cancer in general has been a great challenge for scientists because it is one of the most dangerous diseases for humans in terms of its progression and mortality. For its part, lung cancer is even worse for the life expectancy of those who suffer from it.
There is no doubt that the results set a very important precedent because it is irrefutable proof that using two practices at an early stage will not only reduce pathological progression, but will also guarantee better living conditions for people.
So, what an advance of such historical magnitude will do is lay new foundations for medical treatment of lung cancer and other types. Therefore, it will open the doors to further research on new possibilities that mitigate its negative impact on humans.